Maria Butí Ferret
Maria Butí Ferret
Hospital VAlle Hebron
Verified email at comb.cat
Title
Cited by
Cited by
Year
EASL clinical practice guidelines: management of chronic hepatitis B virus infection
European Association For The Study Of The Liver
Journal of hepatology 57 (1), 167-185, 2012
29142012
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
European Association For The Study Of The Liver
Journal of hepatology 67 (2), 370-398, 2017
25972017
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
N Afdhal, S Zeuzem, P Kwo, M Chojkier, N Gitlin, M Puoti, ...
New England Journal of Medicine 370 (20), 1889-1898, 2014
19542014
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
P Marcellin, E Gane, M Buti, N Afdhal, W Sievert, IM Jacobson, ...
The Lancet 381 (9865), 468-475, 2013
15792013
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B
P Marcellin, EJ Heathcote, M Buti, E Gane, RA de Man, Z Krastev, ...
New England Journal of Medicine 359 (23), 2442-2455, 2008
13372008
Hepatitis C virus antibodies among risk groups in Spain
JI Esteban, L Viladomiu, A Gonzalez, M Roget, J Genesca, R Esteban, ...
The Lancet 334 (8658), 294-297, 1989
11711989
Genomewide association study of severe Covid-19 with respiratory failure
Severe Covid-19 GWAS Group
New England Journal of Medicine 383 (16), 1522-1534, 2020
9912020
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ...
The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018
7632018
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients …
NC Tassopoulos, R Volpes, G Pastore, J Heathcote, M Buti, RD Goldin, ...
Hepatology 29 (3), 889-896, 1999
7511999
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
S Zeuzem, M Buti, P Ferenci, J Sperl, Y Horsmans, J Cianciara, E Ibranyi, ...
Journal of hepatology 44 (1), 97-103, 2006
6602006
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
EJ Heathcote, P Marcellin, M Buti, E Gane, A Robert, Z Krastev, ...
Gastroenterology 140 (1), 132-143, 2011
5992011
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
M Cornberg, HA Razavi, A Alberti, E Bernasconi, M Buti, C Cooper, ...
Liver International 31, 30-60, 2011
5392011
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised …
M Manns, P Marcellin, F Poordad, ESA De Araujo, M Buti, Y Horsmans, ...
The Lancet 384 (9941), 414-426, 2014
5072014
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ...
Journal of viral hepatitis 21, 34-59, 2014
4912014
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 …
M Manns, D Samuel, EJ Gane, D Mutimer, G McCaughan, M Buti, ...
The Lancet Infectious Diseases 16 (6), 685-697, 2016
4382016
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease
YF Liaw, IS Sheen, CM Lee, US Akarca, GV Papatheodoridis, ...
Hepatology 53 (1), 62-72, 2011
3782011
Hepatitis E virus epidemiology in industrialized countries
P Clemente-Casares, S Pina, M Buti, R Jardi, M Martín, S Bofill-Mas, ...
Emerging infectious diseases 9 (4), 449, 2003
3642003
Historical epidemiology of hepatitis C virus (HCV) in selected countries
P Bruggmann, T Berg, ALH Øvrehus, C Moreno, CE Brandão Mello, ...
Journal of viral hepatitis 21, 5-33, 2014
3562014
Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naive genotype 1 hepatitis C: the randomized PILLAR study
MW Fried, M Buti, GJ Dore, R Flisiak, P Ferenci, I Jacobson, P Marcellin, ...
Hepatology 58 (6), 1918-1929, 2013
3502013
Hepatitis C virus infection
MP Manns, M Buti, ED Gane, JM Pawlotsky, H Razavi, N Terrault, ...
Nature reviews Disease primers 3 (1), 1-19, 2017
3242017
The system can't perform the operation now. Try again later.
Articles 1–20